Usefulness of Somatostatin Receptor Scintigraphy (Tc-99m-[HYNIC, Tyr3]-Octreotide) and I-123-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography

作者：Michalowska Ilona; Cwikla Jaroslaw B; Peczkowska Mariola^*; Furmanek Mariusz I; Buscombe John R; Michalski Wojciech; Prejbisz Aleksander; Szperl Malgorzata; Malinoc Angelica; Moczulski Dariusz; Szutkowski Zbigniew; Kawecki Andrzej; Antoniewicz Jolanta; Peczkowski Piotr; Lewczuk Anna; Otto Maciej; Cichocki Andrzej; Bednarek Tupikowska Grazyna; Kabat Marek; Janaszek Sitkowska Hanna; Przybylowska Katarzyna; Janas Jadwiga; Neumann Hartmut P H; Januszewicz Andrzej

来源：Neuroendocrinology, 2015, 101(4): 321-330.

DOI：10.1159/000381458

• Somatostatin receptor scintigraphy
• Metaiodobenzylguanidine
• Computed tomography
• Paraganglioma-pheochromocytoma syndromes
• SDHx gene mutations

Aims: The aim of this study was to assess the usefulness of somatostatin receptor scintigraphy (SRS) using Tc-99m-[HYNIC, Tyr3]-octreotide (TOC) and I-123-metaiodobenzylguanidine (mIBG) in patients with SDHx-related syndromes in which paragangliomas were detected by computed tomography and to establish an optimal imaging diagnostic algorithm in SDHx mutation carriers. Methods: All carriers with clinical and radiological findings suggesting paragangliomas were screened by SRS and I-123-mIBG. Lesions were classified by body regions, i.e. head and neck, chest, abdomen with pelvis and adrenal gland as well as metastasis. Results: We evaluated 46 SDHx gene mutation carriers (32 index cases and 14 relatives; 28 SDHD, 16 SDHB and 2 SDHC). In this group, 102 benign tumors were found in 39 studied patients, and malignant disease was diagnosed in 7 patients. In benign tumors, the sensitivity of SRS was estimated at 77% and of I-123-mIBG at 22.0%. The SRS and mIBG sensitivity was found to be clearly region dependent (p < 0.001). The highest SRS sensitivity was found in head and neck paragangliomas (HNP; 91.4%) and the lowest was found in abdominal paraganglionnas and pheochromocytomas (40 and 42.9%, respectively). The highest I-123-mIBG sensitivity was found in pheochromocytomas (sensitivity of 100%) and the lowest in HNP (sensitivity of 3.7%). In metastatic disease, SRS was superior to mIBG (sensitivity of 95.2 vs. 23.8%, respectively). Conclusion: SRS and I-123-mIBG single photon emission computed tomography (SPECT) sensitivity in SDHx patients is highly body region dependent. In malignant tumors, SRS is superior to I-123-mIBG SPECT.

• 出版日期2015